BR112021024447A2 - Tratamentos de angioedema - Google Patents

Tratamentos de angioedema

Info

Publication number
BR112021024447A2
BR112021024447A2 BR112021024447A BR112021024447A BR112021024447A2 BR 112021024447 A2 BR112021024447 A2 BR 112021024447A2 BR 112021024447 A BR112021024447 A BR 112021024447A BR 112021024447 A BR112021024447 A BR 112021024447A BR 112021024447 A2 BR112021024447 A2 BR 112021024447A2
Authority
BR
Brazil
Prior art keywords
treatments
angioedema
aenh
demand
present
Prior art date
Application number
BR112021024447A
Other languages
English (en)
Inventor
Andreas Maetzel
Martyn Yea Christopher
Paul Feener Edward
David Smith Michael
Louise Marsh Sally
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of BR112021024447A2 publication Critical patent/BR112021024447A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

tratamentos de angioedema. a presente invenção refere-se a tratamentos de angioedema, e especificamente a angioedema mediado por bradicinina não hereditário (bk-aenh). em particular, a presente invenção apresenta tratamentos sob demanda de angioedema mediado por bradicinina não hereditária (bk-aenh) mediante a administração oral de um inibidor de calicreína do plasma a um paciente em necessidade do mesmo sob demanda. tratamentos regulares (ou contínuos) de bk-aenh também são apresentados.
BR112021024447A 2019-06-14 2020-06-15 Tratamentos de angioedema BR112021024447A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861758P 2019-06-14 2019-06-14
GBGB1910125.2A GB201910125D0 (en) 2019-07-15 2019-07-15 Treatments of angioedema
PCT/GB2020/051441 WO2020249979A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema

Publications (1)

Publication Number Publication Date
BR112021024447A2 true BR112021024447A2 (pt) 2022-01-18

Family

ID=67700187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024447A BR112021024447A2 (pt) 2019-06-14 2020-06-15 Tratamentos de angioedema

Country Status (17)

Country Link
US (1) US20220226293A1 (pt)
EP (1) EP3982961A1 (pt)
JP (1) JP2022537913A (pt)
KR (1) KR20220024221A (pt)
CN (2) CN113993520A (pt)
AR (1) AR119159A1 (pt)
AU (1) AU2020293616A1 (pt)
BR (1) BR112021024447A2 (pt)
CA (1) CA3142220A1 (pt)
CL (2) CL2021003243A1 (pt)
GB (1) GB201910125D0 (pt)
IL (1) IL288612A (pt)
MA (1) MA56188A (pt)
MX (1) MX2021014558A (pt)
SG (1) SG11202113375PA (pt)
TW (1) TW202112371A (pt)
WO (1) WO2020249979A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
SI3305778T1 (sl) 2013-05-23 2022-04-29 Kalvista Pharmaceuticals Limited Zaviralci plazemskega kalikreina
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor

Also Published As

Publication number Publication date
JP2022537913A (ja) 2022-08-31
CN113993520A (zh) 2022-01-28
CN118078821A (zh) 2024-05-28
CL2021003243A1 (es) 2022-09-30
MA56188A (fr) 2022-04-20
TW202112371A (zh) 2021-04-01
US20220226293A1 (en) 2022-07-21
SG11202113375PA (en) 2021-12-30
GB201910125D0 (en) 2019-08-28
MX2021014558A (es) 2022-04-06
WO2020249979A1 (en) 2020-12-17
KR20220024221A (ko) 2022-03-03
CA3142220A1 (en) 2020-12-17
AR119159A1 (es) 2021-12-01
AU2020293616A1 (en) 2022-01-27
CL2023000699A1 (es) 2023-10-30
EP3982961A1 (en) 2022-04-20
IL288612A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
BR112021024447A2 (pt) Tratamentos de angioedema
CL2021003244A1 (es) Tratamientos de angioedema hereditario
WO2018067512A8 (en) SPIROCYCLIC COMPOUNDS
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EP4282489A3 (en) Treatment of clostridium difficile infection
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
MX2017001587A (es) Terapia de combinacion para tratar un paramixovirus.
BR112019007977A2 (pt) composto, composição farmacêutica, método de tratamento ou prevenção de câncer, e, uso de um composto
BR112018010360A2 (pt) fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
BR112016005286A2 (pt) composições e métodos compreendendo variantes de protease do clado lg12
MX2021007773A (es) Compuestos inhibidores de egfr.
BR112015023207A8 (pt) composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
BR112016016274A2 (pt) Ponte da barreira hematoencefálica
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
BR112017018522A2 (pt) composições e métodos para diagnóstico e tratamento do câncer
BR112018011622A2 (pt) método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
BR112017017060A2 (pt) ?tratamento?
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
MX360857B (es) Régimen de dosificación para inhibidores de janus quinasa (jak).
MX2017012553A (es) Compuestos espirociclicos.
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
EA201591808A1 (ru) Композиции и способы лечения грибковых и бактериальных патогенов